Table 4.

Controlled trials of growth factors after induction therapy in AML.

Study n Reduction in Days to ANC 1000/μL Documented Reduced Morbidity

GM-CSF (sargramostim)
  Büchner, 1991 86 6–9 +
  Rowe, 1995 117 6 +
GM-CSF (molgrastim)
  Stone, 1995 379 2
  Zittoun, 1996 53 -
  Lowenberg, 1997 316 5
  Witz, 1998 209 6
  Löfgren, 2004 110 8
G-CSF (lenograstim)
  Dombert, 1995 173 6 +
  Link, 1996 187 6 +
  Goldstone, 2001 803 5
  Amadori, 2005 722 5 +
G-CSF (filgrastim)
  Ohno, 1990 67 12 +
  Ohno, 1994 58 6
  Heil, 1997 521 5 +
  Godwin, 1998 234 3–4 +
  Usuki, 2002 270 6 +
  Lehrnbecher, 2007 317 5
  Estey, 1994 197 13

Published with permission from Rowe JM and Avivi I.19

ANC, absolute neutrophil count; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2013 January; 4(1): e0004. ISSN: 2076-9172
Published online 2013 January 30. doi: 10.5041/RMMJ.10104.